In vitro metabolic fate of alizapride: Evidence for the formation of reactive metabolites based on liquid chromatography-tandem mass spectrometry

Journal of Mass Spectrometry

Volumn 47, Issue 6, 2012, Pages 737-750

  Aprile, Silvio ^a   Del Grosso, Erika ^a   Grosa, Giorgio ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Acrolein; Alizapride; LC MS; Microsomes; Reactive metabolites

Indexed keywords

ACROLEIN; ALIZAPRIDE; LC-MS; MICROSOMES; REACTIVE METABOLITES;

ALDEHYDES; ELECTROSPRAY IONIZATION; HERBICIDES; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLISM; METABOLITES; PHYSIOLOGY;

BIOMOLECULES;

ACROLEIN; ALIZAPRIDE; DRUG METABOLITE; EPOXIDE;

ANIMAL CELL; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; DEALKYLATION; DRUG METABOLISM; DRUG OXIDATION; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MALE; METABOLITE; NONHUMAN; NUCLEOPHILICITY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; TANDEM MASS SPECTROMETRY;

ACROLEIN; AMIDES; ANIMALS; CHROMATOGRAPHY, LIQUID; EPOXY COMPOUNDS; FEMALE; HUMANS; MALE; MICROSOMES; MICROSOMES, LIVER; PYRROLIDINES; RATS; RATS, WISTAR; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY;

EID: 84862183005     PISSN: 10765174     EISSN: 10969888     Source Type: Journal    
DOI: 10.1002/jms.3011     Document Type: Article

References (23)

1. A. P. Li. Overview: Evaluation of metabolism-based drug toxicity in drug development. Chem. Biol. Interact. 2009, 179, 1.
2. T. A. Baillie. Future of toxicology-metabolic activation and drug design: challenges and opportunities in chemical toxicology. Chem. Res. Toxicol. 2006, 19, 889.
3. R. Kostiainen, T. Kotiaho, T. Kuuranne, S. Auriola. Liquid chromatography/atmospheric pressure ionization-mass spectrometry in drug metabolism studies. J. Mass Spectrom. 2003, 38, 357.
4. M. Shuguang, R. Subramanian. Detecting and characterizing reactive metabolites by liquid chromatography/tandem mass spectrometry. J. Mass Spectrom. 2006, 41, 1121.
5. G. Aldini, I. Dalle-Donne, R. Maffei Facino, A. Milzani, M. Carini. Intervention strategies to inhibit protein carbonylation by lipoperoxidation- derived reactive carbonyls. Med. Res. Rev. 2007, 27, 817.
6. L. M. Sayre, D. Lin, Q. Yuan, X. Zhu, Y. Tang. Protein adducts generated from products of lipid peroxidation: focus on the HNE and ONE. Drug Metab. Rev. 2006, 38, 651.
7. S. M. Ludeman. The chemistry of the metabolites of cyclophosphamide. Curr. Pharm. Des. 1999, 5, 627.
8. J. Zhang, Q. Tian, S. Yung Chan, S. Chuen Li, S. Zhou, W. Duan, Y. Z. Zhu. Metabolism and transport of oxazaphosphorines and the clinical implications. Drug Metab. Rev. 2005, 37, 611.
9. B. Bonn, C. M. Masimirembwa, N. Castagnoli Jr. Exploration of catalytic properties of CYP2D6 and CYP3A4 through metabolic studies of levorphanol and levallorphan. Drug Metab. Dispos. 2010, 38, 187.
10. W. B. Fang, Y. Chang, E. F. McCance-Katz, D. E. Moody. Determination of naloxone and nornaloxone (noroxymorphone) by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry. J. Anal. Toxicol. 2009, 33, 409.
11. H. Bleiberg, B. Gerard, O. Dalesio, N. Crespeigne, M. Rozencweig. Activity of a new antiemetic agent: alizapride. A randomized double-blind crossover controlled trial. Cancer Chemother. Pharmacol. 1988, 22, 316.
12. C. Laville, J. Margarit. Pharmacodynamics of alizapride. Sem. Hop. 1982, 58, 323.
13. E. Rey, E. Stettler, P. D'athis, G. Pons. Pharmacokinetics of alizapride in children receiving chemotherapy for solid tumour. Fundam. Clin. Pharmacol. 2001, 15, 217.
14. I. Tamaro, S. Aprile, G. B. Giovenzana, G. Grosa. Development and validation of a stability-indicating HPLC-UV method for the determination of alizapride and its degradation products. J. Pharm. Biomed. Anal. 2010, 51, 1024.
15. I. Monkovic, D. Willner, M. A. Adam, M. Brown, R. R. Crenshaw, C. E. Fuller, P. F. Juby, G. M. Luke, J. A. Matiskella, T. A. Montzka. Substituted benzamides.1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis. J. Med. Chem. 1988, 31, 1548.
16. G. Grosa, U. Galli, B. Rolando, R. Fruttero, G. Gervasio, A. Gasco. Identification of 2,3-diaminophenazine and of o-benzoquinone dioxime as the major in vitro metabolites of benzofuroxan. Xenobiotica 2004, 34, 345.
17. T. Omura, R. Sato. The carbon monoxide binding pigment of liver microsomes. J. Biol. Chem. 1964, 39, 3137.
18. R. N. Brogden, R. C. Heel, T. M. Speight, G. S. Avery. Alclofenac: a review of its pharmacological properties and therapeutic efficacy in rheumatoid arthritis and allied rheumatic disorders. Drugs 1977, 14, 241.
19. R. D. Mann. Withdrawal of alclofenac (Prinalgin). Br. Med. J. 1979, 2, 133.
20. J. F. Hort. Adverse reactions to alclofenac. Curr. Med. Res. Opin. 1975, 3, 333.
21. D. Mulliner, D. Wondrousch, G. Schuurmann. Predicting Michael-acceptor reactivity and toxicity through quantum chemical transitionstate calculations. Org. Biomol. Chem. 2011, 9, 8400.
22. H. Hoffmann, R. Pooth. Biotransformation of 1H-benzotriazole and N-1-alkylbenzotriazoles in vitro. Arch. Pharm. 1982, 315, 422.
23. J. Hukkanen, P. Jacob III, N. L. Benowitz. Metabolism and Disposition Kinetics of Nicotine. Pharmacol. Rev. 2005, 57, 115.